RIBOMIC Inc.
- Biotech or pharma, therapeutic R&D
Ribomic Inc. is a clinical stage pharmaceutical company dedicated to advancing aptamer therapeutics, with a particular focus on rare diseases and ophthalmology. Its lead candidate, RBM-007, is in Phase 2a for achondroplasia, and has also completed Phase 1/2a for wet AMD.
Leveraging our proprietary aptamer discovery platform—known for its high hit rate and generation of aptamers with strong affinity—we have successfully created numerous aptamer drug candidates. Building on these strengths, we are now also actively applying our platform to the development of aptamer-based drug delivery systems (DDS).
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}